Lexeo Therapeutics (LXEO) Competitors $3.93 +0.36 (+10.08%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. VERV, PGEN, MAZE, PRTC, ABVX, AUTL, ETON, RVNC, RAPP, and AMLXShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Verve Therapeutics (VERV), Precigen (PGEN), Maze Therapeutics (MAZE), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), Revance Therapeutics (RVNC), Rapport Therapeutics (RAPP), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Verve Therapeutics Precigen Maze Therapeutics PureTech Health ABIVAX Société Anonyme Autolus Therapeutics Eton Pharmaceuticals Revance Therapeutics Rapport Therapeutics Amylyx Pharmaceuticals Lexeo Therapeutics (NASDAQ:LXEO) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations. Do insiders & institutionals have more ownership in LXEO or VERV? 60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 4.5% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in LXEO or VERV? Verve Therapeutics received 7 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 61.11% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes26100.00% Underperform VotesNo VotesVerve TherapeuticsOutperform Votes3361.11% Underperform Votes2138.89% Which has stronger earnings & valuation, LXEO or VERV? Lexeo Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K200.71-$66.39M-$3.08-1.28Verve Therapeutics$32.33M15.63-$200.07M-$2.35-2.41 Is LXEO or VERV more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. Verve Therapeutics' return on equity of -35.23% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Verve Therapeutics -807.65%-35.23%-27.65% Does the media refer more to LXEO or VERV? In the previous week, Verve Therapeutics had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for Verve Therapeutics and 5 mentions for Lexeo Therapeutics. Verve Therapeutics' average media sentiment score of 1.28 beat Lexeo Therapeutics' score of 1.26 indicating that Verve Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verve Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LXEO or VERV? Lexeo Therapeutics currently has a consensus target price of $22.20, suggesting a potential upside of 464.89%. Verve Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 354.14%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, LXEO or VERV? Lexeo Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. SummaryVerve Therapeutics beats Lexeo Therapeutics on 11 of the 19 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.46M$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.2430.4222.4418.48Price / Sales200.71498.92394.09103.59Price / CashN/A168.6838.1834.62Price / Book0.923.206.774.25Net Income-$66.39M-$72.35M$3.22B$248.23M7 Day Performance7.08%1.46%1.49%0.89%1 Month Performance25.56%8.79%4.00%3.53%1 Year Performance-68.05%-22.36%16.21%5.08% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.8924 of 5 stars$3.93+10.1%$22.20+464.9%-68.4%$130.46M$650,000.00-1.2458Positive NewsHigh Trading VolumeVERVVerve Therapeutics3.715 of 5 stars$4.78+4.1%$25.75+438.7%-5.7%$424.45M$32.33M-1.94110High Trading VolumePGENPrecigen3.6732 of 5 stars$1.37-1.4%$7.00+410.9%+18.2%$402.84M$3.93M-2.49190News CoveragePositive NewsGap DownMAZEMaze TherapeuticsN/A$9.13+8.6%$25.67+181.1%N/A$399.86M$167.50M0.00121PRTCPureTech Health2.0068 of 5 stars$16.64-0.6%$45.00+170.5%-38.1%$399.56M$3.33M0.00100News CoverageGap DownABVXABIVAX Société Anonyme2.2258 of 5 stars$6.23-2.7%$38.00+510.0%-52.5%$395.10MN/A0.0061Analyst ForecastNews CoverageGap UpAUTLAutolus Therapeutics2.6974 of 5 stars$1.44+0.7%$9.32+547.2%-61.7%$383.18M$10.12M-1.19330Upcoming EarningsPositive NewsGap DownETONEton Pharmaceuticals2.3464 of 5 stars$14.26-0.6%$27.67+94.0%+381.4%$382.43M$39.01M-64.8220Upcoming EarningsAnalyst RevisionNews CoverageGap UpRVNCRevance Therapeutics2.0952 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsAnalyst ForecastRAPPRapport Therapeutics2.442 of 5 stars$10.38+2.3%$32.67+214.7%N/A$378.83MN/A-0.75N/AAMLXAmylyx Pharmaceuticals3.0333 of 5 stars$4.23+6.3%$8.00+89.1%+182.3%$374.79M$87.37M-1.11200Upcoming EarningsPositive News Related Companies and Tools Related Companies Verve Therapeutics Competitors Precigen Competitors Maze Therapeutics Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Autolus Therapeutics Competitors Eton Pharmaceuticals Competitors Revance Therapeutics Competitors Rapport Therapeutics Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXEO Stock Free LXEO Stock Alerts